The ePharmacy market would grow at a CAGR of 17.51% over the predicted time frame. The market is expected to increase in value from US$ 70.42 Bn in 2022 to US$ 256 Bn in 2030.
The on ePharmacy
Market, which provides a business strategy, research & development
activities, concise outline of the market valuation, valuable insights
pertaining to market share, size, supply chain analysis, competitive landscape
and regional proliferation of this industry.
Download
Free Sample@ https://www.precedenceresearch.com/sample/1793
Report Scope of the ePharmacy Market
| Report Coverage | Details |
| Market Size by 2030 | USD 256 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 17.51% |
| North America Market Share in 2021 | 41% |
| OTC Products Segment Market Share in 2021 | 70% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Product, Type, Drug Type, Operating Platform, Platform, Payment Method, Business Model, Geography |
A recent
report provides crucial insights along with application based and forecast
information in the Global EPharmacy Market. The report provides a comprehensive
analysis of key factors that are expected to drive the growth of this market.
This study also provides a detailed overview of the opportunities along with
the current trends observed in the EPharmacy market.
A
quantitative analysis of the industry is compiled for a period of 10 years in
order to assist players to grow in the market. Insights on specific revenue
figures generated are also given in the report, along with projected revenue at
the end of the forecast period.
Companies
and Manufacturers Covered
The study
covers key players operating in the market along with prime schemes and
strategies implemented by each player to hold high positions in the industry.
Such a tough vendor landscape provides a competitive outlook of the industry,
consequently existing as a key insight. These insights were thoroughly analysed
and prime business strategies and products that offer high revenue generation
capacities were identified. Key players of the global EPharmacy market are
included as given below:
EPharmacy Market Key Players
- The Kroger Co.
- DocMorris
- Walgreen Co.
- Rowlands Pharmacy
- Giant Eagle, Inc.
- Optum Rx, Inc.
- Walmart, Inc.
- CVS Health
- Express Scripts Holding Company
- Netmeds
Market Segments
Report Objectives
- To define, describe, and forecast the global ePharmacy
market based on product, and region
- To provide detailed information regarding the major
factors influencing the growth of the market (drivers, opportunities, and
industry-specific challenges)
- To strategically analyze micromarkets1 with respect to
individual growth trends, future prospects, and contributions to the total
market
- To analyze opportunities in the market for stakeholders
and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to
four main regions—North America,
Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively
analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as
acquisitions, expansions, new product launches, and partnerships in the ePharmacy
market
Table of Content
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global ePharmacy Market, By Product
7.1. ePharmacy Market, by Product, 2022-2030
7.1.1. Over-the-Counter (OTC) Products
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Prescription Medicine
7.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global ePharmacy Market, By Type
8.1. ePharmacy Market, by Type, 2022-2030
8.1.1. Analgesics
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Skin Care
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Dental
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Cold and Flu
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Vitamins & Minerals
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Weight Loss
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Other
8.1.7.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global ePharmacy Market, By Drug Type
9.1. ePharmacy Market, by Drug Type, 2022-2030
9.1.1. Foam Dressings
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Film Dressings
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Hydrocolloid Dressings
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. CHG Adhesive Dressings
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Alginate Dressing
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Surgical Tapes
9.1.6.1. Market Revenue and Forecast (2017-2030)
9.1.7. Hydrogel Dressings
9.1.7.1. Market Revenue and Forecast (2017-2030)
9.1.8. Collagen Dressings
9.1.8.1. Market Revenue and Forecast (2017-2030)
9.1.9. Barrier Tapes
9.1.9.1. Market Revenue and Forecast (2017-2030)
9.1.10. Tissue Sealants
9.1.10.1. Market Revenue and Forecast (2017-2030)
9.1.11. Negative Pressure Wound Therapy Drapes
9.1.11.1. Market Revenue and Forecast (2017-2030)
9.1.12. Others
9.1.12.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global ePharmacy Market, By Operating Platform
10.1. ePharmacy Market, by Operating Platform, 2022-2030
10.1.1. Diabetic Foot Ulcers
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Pressure Ulcers
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Surgical and Traumatic Wounds
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Burns
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Ostomy Care
10.1.5.1. Market Revenue and Forecast (2017-2030)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global ePharmacy Market, By Platform
11.1. ePharmacy Market, by Platform, 2022-2030
11.1.1. Mobile Users
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Desktop Users
11.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global ePharmacy Market, By Payment Method
12.1. ePharmacy Market, by Payment Method, 2022-2030
12.1.1. Cash on Delivery
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Online Payment
12.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global ePharmacy Market, By Business Model
13.1. ePharmacy Market, by Business Model, 2022-2030
13.1.1. Hospitals and Clinics
13.1.1.1. Market Revenue and Forecast (2017-2030)
13.1.2. Home Care Settings
13.1.2.1. Market Revenue and Forecast (2017-2030)
13.1.3. Others
13.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 14. Global ePharmacy Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Product (2017-2030)
14.1.2. Market Revenue and Forecast, by Type (2017-2030)
14.1.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.1.5. Market Revenue and Forecast, by Platform (2017-2030)
14.1.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.1.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.1.8. U.S.
14.1.8.1. Market Revenue and Forecast, by Product (2017-2030)
14.1.8.2. Market Revenue and Forecast, by Type (2017-2030)
14.1.8.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.8.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.1.8.5. Market Revenue and Forecast, by Platform (2017-2030)
14.1.8.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.1.8.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Product (2017-2030)
14.1.9.2. Market Revenue and Forecast, by Type (2017-2030)
14.1.9.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.9.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.1.9.5. Market Revenue and Forecast, by Platform (2017-2030)
14.1.9.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.1.9.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.2. Europe
14.2.1. Market Revenue and Forecast, by Product (2017-2030)
14.2.2. Market Revenue and Forecast, by Type (2017-2030)
14.2.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.2.5. Market Revenue and Forecast, by Platform (2017-2030)
14.2.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.2.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Product (2017-2030)
14.2.8.2. Market Revenue and Forecast, by Type (2017-2030)
14.2.8.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.8.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.2.8.5. Market Revenue and Forecast, by Platform (2017-2030)
14.2.8.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.2.8.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.2.9. Germany
14.2.9.1. Market Revenue and Forecast, by Product (2017-2030)
14.2.9.2. Market Revenue and Forecast, by Type (2017-2030)
14.2.9.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.9.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.2.9.5. Market Revenue and Forecast, by Platform (2017-2030)
14.2.9.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.2.9.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.2.10. France
14.2.10.1. Market Revenue and Forecast, by Product (2017-2030)
14.2.10.2. Market Revenue and Forecast, by Type (2017-2030)
14.2.10.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.10.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.2.10.5. Market Revenue and Forecast, by Platform (2017-2030)
14.2.10.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.2.10.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Forecast, by Product (2017-2030)
14.2.11.2. Market Revenue and Forecast, by Type (2017-2030)
14.2.11.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.11.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.2.11.5. Market Revenue and Forecast, by Platform (2017-2030)
14.2.11.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.2.11.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Product (2017-2030)
14.3.2. Market Revenue and Forecast, by Type (2017-2030)
14.3.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.3.5. Market Revenue and Forecast, by Platform (2017-2030)
14.3.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.3.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.3.8. India
14.3.8.1. Market Revenue and Forecast, by Product (2017-2030)
14.3.8.2. Market Revenue and Forecast, by Type (2017-2030)
14.3.8.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.8.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.3.8.5. Market Revenue and Forecast, by Platform (2017-2030)
14.3.8.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.3.8.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.3.9. China
14.3.9.1. Market Revenue and Forecast, by Product (2017-2030)
14.3.9.2. Market Revenue and Forecast, by Type (2017-2030)
14.3.9.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.9.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.3.9.5. Market Revenue and Forecast, by Platform (2017-2030)
14.3.9.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.3.9.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.3.10. Japan
14.3.10.1. Market Revenue and Forecast, by Product (2017-2030)
14.3.10.2. Market Revenue and Forecast, by Type (2017-2030)
14.3.10.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.10.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.3.10.5. Market Revenue and Forecast, by Platform (2017-2030)
14.3.10.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.3.10.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Forecast, by Product (2017-2030)
14.3.11.2. Market Revenue and Forecast, by Type (2017-2030)
14.3.11.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.11.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.3.11.5. Market Revenue and Forecast, by Platform (2017-2030)
14.3.11.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.3.11.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Product (2017-2030)
14.4.2. Market Revenue and Forecast, by Type (2017-2030)
14.4.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.4.5. Market Revenue and Forecast, by Platform (2017-2030)
14.4.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.4.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.4.8. GCC
14.4.8.1. Market Revenue and Forecast, by Product (2017-2030)
14.4.8.2. Market Revenue and Forecast, by Type (2017-2030)
14.4.8.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.8.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.4.8.5. Market Revenue and Forecast, by Platform (2017-2030)
14.4.8.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.4.8.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.4.9. North Africa
14.4.9.1. Market Revenue and Forecast, by Product (2017-2030)
14.4.9.2. Market Revenue and Forecast, by Type (2017-2030)
14.4.9.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.9.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.4.9.5. Market Revenue and Forecast, by Platform (2017-2030)
14.4.9.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.4.9.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.4.10. South Africa
14.4.10.1. Market Revenue and Forecast, by Product (2017-2030)
14.4.10.2. Market Revenue and Forecast, by Type (2017-2030)
14.4.10.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.10.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.4.10.5. Market Revenue and Forecast, by Platform (2017-2030)
14.4.10.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.4.10.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Forecast, by Product (2017-2030)
14.4.11.2. Market Revenue and Forecast, by Type (2017-2030)
14.4.11.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.11.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.4.11.5. Market Revenue and Forecast, by Platform (2017-2030)
14.4.11.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.4.11.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Product (2017-2030)
14.5.2. Market Revenue and Forecast, by Type (2017-2030)
14.5.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.5.5. Market Revenue and Forecast, by Platform (2017-2030)
14.5.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.5.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.5.8. Brazil
14.5.8.1. Market Revenue and Forecast, by Product (2017-2030)
14.5.8.2. Market Revenue and Forecast, by Type (2017-2030)
14.5.8.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.8.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.5.8.5. Market Revenue and Forecast, by Platform (2017-2030)
14.5.8.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.5.8.7. Market Revenue and Forecast, by Payment Method (2017-2030)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Product (2017-2030)
14.5.9.2. Market Revenue and Forecast, by Type (2017-2030)
14.5.9.3. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.9.4. Market Revenue and Forecast, by Operating Platform (2017-2030)
14.5.9.5. Market Revenue and Forecast, by Platform (2017-2030)
14.5.9.6. Market Revenue and Forecast, by Business Model (2017-2030)
14.5.9.7. Market Revenue and Forecast, by Payment Method (2017-2030)
Chapter 15. Company Profiles
15.1. The Kroger Co.
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. DocMorris
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Walgreen Co.
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Rowlands Pharmacy
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Giant Eagle, Inc.
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Optum Rx, Inc.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Walmart, Inc.
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. CVS Health
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Express Scripts Holding Company
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments